Shionogi & Co., Ltd.

Impact of the 2011 Great Eastern Japan Earthquake (3rd Report)

Osaka, Japan, April 4, 2011 - Shionogi would like to express condolences to the victims and
sincerely hope for the recovery of the people affected by the disaster of the Tohoku earthquake
occurred on March 11, 2011.
The operation of Shionogi affected by the earthquake was announced officially in the 2nd report on
March 16, 2011. As of today, we would like to make an announcement of the current operation of
Shionogi as follows.

1. Facility situation
Manufacturing of main antibiotics and cancer pain analgesic are expected to gradually recover from
April 11, 2011 in Kanegasaki Plant (Kanegasaki-cho, Isawa-gun, Iwate) where we have suspended
all operations due to the damages caused by the earthquake.

2. Product supply
At this moment, we are assuming that there is little impact on the supply of our main products
including the products manufactured in Kanegasaki Plant.
We will promptly make an announcement if we find any concern about the stable supply of
products to customers.

3. Medical representative activity
The sales and marketing activities are recovering to a routine practice except in part of Fukushima
Prefecture while considering social conditions and situations of medical institutions.

4. Impact on business performance
The impact on business performance as a result of the earthquake is currently under inspection.
Shionogi will quickly make an announcement in case a significant impact on business performance
of Shionogi group is expected.

Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light
of the information currently available, assumptions that are subject to risks and uncertainties which could
cause actual results to differ materially from these statements. Risks and uncertainties include general
domestic and international economic conditions such as general industry and market conditions, and
changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with
respect to product-related forward-looking statements. Product risks and uncertainties include, but are not
limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and
concerns about product safety and efficacy; technological advances; adverse outcome of important
litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing
products, there are manufacturing and marketing risks, which include, but are not limited to, inability to
build production capacity to meet demand, unavailability of raw materials and entry of competitive products.
The company disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.

For further information, contact:
Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885
Fax: +81-6-6229-9596